Balaxi Pharmaceuticals Limited

April 13, 2023

To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Reconciliation of Share Capital Audit Report

Dear Sir/Madam,

Please find enclosed the Reconciliation of Share Capital Audit Report for Equity Shares of the Company for the quarter ended March 31, 2023. The report has been signed by Mr. Yogindunath S of BVR & Associates Company Secretaries LLP.

This report is submitted in compliance with Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Udayan Shukla (Company Secretary & Compliance Officer) Membership No.: F11744

Encl: As above

Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 Email: info@balaxi.in Website: www.balaxipharma.in

$\mathbb{B} \vee \mathbb{R}$ & associates

Company Secretaries LLP

LLP Identification No: AAE-7079

To,

Balaxi Pharmaceuticals Limited

Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad (T.G.) - 500096

Dear Sir/ Madam,

We have examined the relevant books, registers, forms, documents and papers produced electronically before us by **Balaxi Pharmaceuticals Limited** ('the Company') and its Registrars and Transfer Agent (RTA), Aarthi Consultants Private Limited, in respect of Reconciliation of Share Capital Audit as per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us, we certify the following:

1	For Quarter Ended	March 31, 2023
2	ISIN	INE618N01014
3	Face Value	Rs. 10/- per equity share
4	Name of the Company	Balaxi Pharmaceuticals Limited
5	Registered Office Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096
6	Correspondence Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096
7	Telephone & Fax Nos.	040 23555300
8	Email address	secretarial@balaxi.in
9	Names of the Stock Exchanges where the company's securities are listed:	National Stock Exchange of India
		COCHIN 682 019

18 *

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

"Swastika", First Floor Chitteth House, P C Road Vytilla P. O., Cochin - 682 019 Ph: 0484 4046696, +91 98957 62686

		Number of shares	% of Total Issued Cap.
10	Issued Capital	1,01,81,250	100%
11	Listed Capital (Exchange wise) (as per company records) National Stock Exchange of India Limited (NSE)	1,01,57,500	99.77%
12	Held in dematerialised form in CDSL	77,40,666	76.03%
13	Held in dematerialised form in NSDL	23,75,474	23.33%
14	Physical	65,110	0.64%
15	Total No. of shares (12+13+14)	1,01,81,250	100.00%
16	Reasons for difference if any,		
	between		
(a)	(10&11)	The Board of Director vide circular resolutio 14, 2023, allotted 23,7 Thousand Seven Hu Equity Shares at an 451/- each to the sir who applied for co warrants. As on March 31, 207 had received In prince listing from National India Limited (NSE) by trading approval we listed capital of the C include the aforesait Shares.	n passed on March 750 (Twenty-Three indred and Fifty) issue price of Rs. x warrant holders onversion of the 23, The Company ciple approval for Stock Exchange of ut the final listing/ as pending. The Company does not
×	· · ·	The Corporate Action 23,750 Equity Shares as on March 31, 202 shares are reflected i physical shares.	were also pending 3, and hence, the
(b)	(10&15)	N.A.	
(c)	(11&15)	Same as 16(a) above.	0

CRETARIE

0

SSOCIA:

COCHIN 682 019

* 6

18

17. Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars***	No. of	Applied	Listed on	Whether	Whether	In-prin.
	shares	/ Not	. Stock	intimated	intimated	appr.
		Applied/	Exchanges	to CDSL	to NSDL	pending
· *		for listing			4	for SE
Allotment of	1,16,500	Already	Yes,	Yes	Yes	NA
Equity		Listed	Listed on			
Shares			NSE			
pursuant to						
conversion			0			
of warrants						
on January						
27, 2023						
Allotment of	16,500	Already	Yes,	Yes	Yes	NA
Equity		Listed	Listed on			
Shares		a ¹¹	NSE		22	
pursuant to		-		1. B		
conversion						
of warrants						
on February			•			
15, 2023			9 A)	·		
Allotment of	23,750	Applied	Applied	Yes	Yes	NA
Equity		for final	for final			
Shares		listing/	listing/			
pursuant to		trading	trading			
conversion		approval	approval			
of warrants						
on March 14,						
2023				-		

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

h
- draw
- Poguete

19	Reference of previous quarter with regards to excess dematerialized shares, if any.	NIL
20	Has the company resolved the matter mentioned	Not Applicable
	in point no. 19 above in the current quarter? If not,	
	reason why?	

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 Days	NIL	. NIL	NA
Pending for more than 21 days	NIL	NIL	NA

22	Name, Telephone & Fax No. of the Compliance	Udayan Shukla
	Officer of the Company.	Telephone No.: 040 2355
		5300
		Email: <u>secretarial@balaxi.in</u>
23	Name, Address, Tel. & Fax No., Regn. no. of the	CS. Yogindunath S
,	Practicing Company Secretary certifying the	BVR & Associates
	report	Company Secretaries LLP,
		Swastika, First Floor,
		Chitteth Building, P C
		Road, Vytilla P.O, Cochin-
		682019
		Tel: 0484-4046696
		Membership No.: 7865
		Certificate of Practice No.:
		9137
		Peer Review No.:
		P2010KE020500
	COMPANE	. 9
•	COCHIN 682 019	RECRETARY OF BOUND AND AND AND AND AND AND AND AND AND A
	2 d 18 * dT	

		λ.
24	Appointment of common agency for share registry work (if yes, name and address)	Aarthi Consultants Private Limited 1-2-285, Domalguda, Hyderabad-500029
		Ph: 040-27638111, 27634445 Fax: 040-27632184
25	Any other detail that the Company Secretary may like to provide. (e.g. BIFR company, delisting from SE,	Nil
MIE.	YOGINDUNATH. S. Designated Partner BVR & Associates Company Secretaries LI "Swastika", Chitteth Building PC Road, Ponnurunni (E)	- 1 ogualient



YOGINDUNATH. S. Designated Partner BVR & Associates Company Secretaries LI "Swastika", Chitteth Building PC Road, Ponnurunni (E) Vyttilu P.O., Cochin - 682 019 C P No: \$137, FC\$ 7865 LLP IN AAE - 7079 BVR & Associates C Practic

⁸⁶⁵ CS Yogindunath S BVR & Associates Company Secretaries LLP, Practicing Company Secretaries M NO:7865 CP:9137 UDIN:F007865E000066396

Date: 12/04/2023 Place: Cochin